TY - JOUR
T1 - Low-grade serous ovarian cancer
T2 - A unique disease
AU - Schmeler, Kathleen M.
AU - Gershenson, David M.
PY - 2008
Y1 - 2008
N2 - Low-grade serous carcinomas represent approximately 10% of all serous ovarian carcinomas. A growing body of research has demonstrated several important differences between the clinical and molecular characteristics of these tumors and those of high-grade serous ovarian carcinomas. Patients with low-grade serous ovarian tumors are diagnosed at a younger age, have a longer overall survival, and have lower response rates to conventional chemotherapy. In addition, low-grade serous ovarian carcinomas have pathologic and molecular characteristics distinct from high-grade serous carcinomas, yet similar to serous tumors of low malignant potential. This suggests a common pathogenesis and a continuum of disease from serous tumors of low malignant potential to low-grade serous carcinomas. Further study, focusing specifically on low-grade serous carcinomas, is needed to determine the role of other chemotherapeutic agents, hormonal therapy, or targeted biologic agents in the treatment of this disease.
AB - Low-grade serous carcinomas represent approximately 10% of all serous ovarian carcinomas. A growing body of research has demonstrated several important differences between the clinical and molecular characteristics of these tumors and those of high-grade serous ovarian carcinomas. Patients with low-grade serous ovarian tumors are diagnosed at a younger age, have a longer overall survival, and have lower response rates to conventional chemotherapy. In addition, low-grade serous ovarian carcinomas have pathologic and molecular characteristics distinct from high-grade serous carcinomas, yet similar to serous tumors of low malignant potential. This suggests a common pathogenesis and a continuum of disease from serous tumors of low malignant potential to low-grade serous carcinomas. Further study, focusing specifically on low-grade serous carcinomas, is needed to determine the role of other chemotherapeutic agents, hormonal therapy, or targeted biologic agents in the treatment of this disease.
UR - http://www.scopus.com/inward/record.url?scp=58649099361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58649099361&partnerID=8YFLogxK
U2 - 10.1007/s11912-008-0078-8
DO - 10.1007/s11912-008-0078-8
M3 - Review article
C2 - 18928667
AN - SCOPUS:58649099361
SN - 1523-3790
VL - 10
SP - 519
EP - 523
JO - Current oncology reports
JF - Current oncology reports
IS - 6
ER -